Christopher J Ryerson, Mas

List of Publications by Year in Descending Order

146 papers	10,114 citations	38 h-index	100 g-index
168 ext. papers	14,230 ext. citations	6.7 avg, IF	6.15 L-index

#	Paper	IF	Citations
146	Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD.. *Respiratory Medicine*, **2022**, 195, 106792	4.6	0
145	A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies.. *BMC Pulmonary Medicine*, **2022**, 22, 148	3.5	0
144	YouTube-videos for patient education in lymphangioleiomyomatosis?. *Respiratory Research*, **2022**, 23, 103	7.3	0
143	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. *American Journal of Respiratory and Critical Care Medicine*, **2022**, 205, e18-e47	10.2	38
142	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.. *Respiratory Medicine*, **2021**, 191, 106722	4.6	0
141	Neighborhood-level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	1
140	Association of Body Mass Index and Change in Weight with Mortality in Patients with Fibrotic Interstitial Lung Disease. *Chest*, **2021**,	5.3	1
139	Fibroblast Foci and Patchy Fibrosis Do Not Separate Usual Interstitial Pneumonia From Fibrotic Hypersensitivity Pneumonitis in Transbronchial Cryobiopsies. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 1325-1326	5	0
138	Effects of traffic-related air pollution on exercise endurance, dyspnea and cardiorespiratory physiology in health and COPD - A randomized, placebo-controlled crossover trial. *Chest*, **2021**,	5.3	2
137	Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. *Radiology*, **2021**, 298, 531-549	20.5	10
136	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. *Chest*, **2021**, 159, 1107-1125	5.3	15
135	The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF). *EBioMedicine*, **2021**, 66, 103325	8.8	2
134	Prevalence and prognostic impact of physical frailty in interstitial lung disease: A prospective cohort study. *Respirology*, **2021**, 26, 683-689	3.6	2
133	Nocturnal hypoxaemia in interstitial lung disease: a systematic review. *Thorax*, **2021**, 76, 1200-1208	7.3	1
132	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. *Annals of the American Thoracic Society*, **2021**,	4.7	3
131	Social Media Content of Idiopathic Pulmonary Fibrosis Groups and Pages on Facebook: Cross-sectional Analysis. *JMIR Public Health and Surveillance*, **2021**, 7, e24199	11.4	2
130	Update in Interstitial Lung Disease 2020. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1343-1352	10.2	4

129	A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. *European Respiratory Journal*, **2021**,	13.6	2
128	Pulmonary Apical Cap as a Potential Risk Factor for Pleuroparenchymal Fibroelastosis. *Chest*, **2021**, 159, e365-e370	5.3	1
127	Diagnostic Classification of Interstitial Lung Disease in Clinical Practice. *Clinics in Chest Medicine*, **2021**, 42, 251-261	5.3	1
126	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. *Pharmacology & Therapeutics*, **2021**, 222, 107798	13.9	38
125	Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. *Respiratory Physiology and Neurobiology*, **2021**, 288, 103644	2.8	37
124	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. *Respiratory Research*, **2021**, 22, 202	7.3	0
123	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). *Annals of the Rheumatic Diseases*, **2021**, 80, 143-150	2.4	41
122	Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. *Thorax*, **2021**, 76, 37-43	7.3	8
121	A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. *Thorax*, **2021**, 76, 402-404	7.3	75
120	Reply: Quantitative Computed Tomography in Systemic Sclerosis-Interstitial Lung Disease: Are We Ready to Go beyond Standard Assessment?. *Annals of the American Thoracic Society*, **2021**, 18, 184	4.7	
119	Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. *European Respiratory Journal*, **2021**, 57,	13.6	7
118	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. *Annals of the American Thoracic Society*, **2021**, 18, 1661-1668	4.7	2
117	Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. *European Respiratory Journal*, **2021**, 58,	13.6	21
116	An Updated Assessment of Online Information on Idiopathic Pulmonary Fibrosis. *Annals of the American Thoracic Society*, **2021**, 18, 1421-1423	4.7	2
115	Changes in pulmonary function and patient-reported outcomes during COVID-19 recovery: a longitudinal, prospective cohort study. *ERJ Open Research*, **2021**, 7,	3.5	1
114	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, e3-e23	10.2	1
113	Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. *Thorax*, **2021**,	7.3	3
112	Interstitial lung disease and obstructive sleep apnea. *Sleep Medicine Reviews*, **2021**, 58, 101442	10.2	2

111	Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease: An International Cohort Study. *Chest*, **2021**, 160, 994-1005	5.3	2
110	Pectoralis muscle area and its association with indices of disease severity in interstitial lung disease. *Respiratory Medicine*, **2021**, 186, 106539	4.6	1
109	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. *Lancet Respiratory Medicine,the*, **2021**, 9, 1065-1076	35.1	7
108	The opportunities and challenges of social media in interstitial lung disease: a viewpoint. *Respiratory Research*, **2021**, 22, 247	7.3	
107	Malignancy Risk Associated with Mycophenolate Mofetil or Azathioprine in Patients with Fibrotic Interstitial Lung Disease.. *Chest*, **2021**,	5.3	1
106	Frailty and chronic respiratory disease: the need for a multidisciplinary care model. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2021**, 38, e2021031	1.1	0
105	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. *Respiratory Research*, **2020**, 21, 322	7.3	3
104	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. *Expert Opinion on Investigational Drugs*, **2020**, 29, 797-808	5.9	4
103	Air Pollution and Interstitial Lung Diseases: Defining Epigenomic Effects. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 1217-1224	10.2	4
102	The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Radiology*, **2020**, 296, 172-180	20.5	471
101	A Primer on Interstitial Lung Disease and Thoracic Radiation. *Journal of Thoracic Oncology*, **2020**, 15, 902-913	8.3	14
100	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. *Lancet Respiratory Medicine,the*, **2020**, 8, 726-737	35.1	77
99	Real-world appropriateness of imaging severity thresholds in interstitial lung disease clinical trials. *Lancet Respiratory Medicine,the*, **2020**, 8, e7	35.1	1
98	Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies. *Expert Review of Respiratory Medicine*, **2020**, 14, 405-414	3.8	4
97	Interstitial lung disease. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2020**, 4, S21-S246	2.6	
96	The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. *Chest*, **2020**, 158, 106-116	5.3	384
95	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. *Chest*, **2020**, 158, 1069-1078	5.3	41
94	Progression of fibrosing interstitial lung disease. *Respiratory Research*, **2020**, 21, 32	7.3	39

93	Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. *Open Respiratory Medicine Journal*, **2020**, 14, 22-31	1.1	3
92	Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitis. *Modern Pathology*, **2020**, 33, 616-625	9.8	15
91	Patient-reported outcome measures after COVID-19: a prospective cohort study. *European Respiratory Journal*, **2020**, 56,	13.6	65
90	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2020**, 4, 147-155	0.6	2
89	Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, e121-e141	10.2	37
88	Hypersensitivity pneumonitis. *Nature Reviews Disease Primers*, **2020**, 6, 65	51.1	27
87	Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, e36-e69	10.2	175
86	Cardiopulmonary Exercise Testing in Patients With Interstitial Lung Disease. *Frontiers in Physiology*, **2020**, 11, 832	4.6	2
85	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2020**, 4, 226-228	0.6	1
84	Characterization and determinants of sleep measured by self-report and wrist actigraphy in patients with interstitial lung disease. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2020**, 1-9	0.6	
83	Frailty in patients with interstitial lung disease. *Current Opinion in Pulmonary Medicine*, **2020**, 26, 449-456	3	2
82	Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2020**, 4, 25-30	0.6	
81	Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes. *European Respiratory Journal*, **2020**, 55,	13.6	13
80	Transbronchial lung cryobiopsy in ILD: the data we've been waiting for. *Lancet Respiratory Medicine,the*, **2020**, 8, 129-130	35.1	0
79	Association of Computed Tomography Densitometry with Disease Severity, Functional Decline, and Survival in Systemic Sclerosis-associated Interstitial Lung Disease. *Annals of the American Thoracic Society*, **2020**, 17, 813-820	4.7	12
78	Quality indicators for pulmonary rehabilitation programs in Canada: A Canadian Thoracic Society expert working group report. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2019**, 3, 199-209	0.6	4
77	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. *Chest*, **2019**, 156, 887-895	5.3	5
76	Impact of Psychological Deficits and Pain on Physical Activity of Patients with Interstitial Lung Disease. *Lung*, **2019**, 197, 415-425	2.9	9

75	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. *ERJ Open Research*, **2019**, 5,	3.5	12
74	Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study. *Respiratory Research*, **2019**, 20, 56	7.3	15
73	Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. *European Respiratory Journal*, **2019**, 53,	13.6	5
72	Qualitative dimensions of exertional dyspnea in fibrotic interstitial lung disease. *Respiratory Physiology and Neurobiology*, **2019**, 266, 1-8	2.8	6
71	Update in the diagnostic approach to fibrotic interstitial lung disease. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2019**, 3, 155-159	0.6	
70	Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis. *Annals of the American Thoracic Society*, **2019**, 16, 1327-1329	4.7	6
69	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1146-1153	10.2	33
68	Exercise Pathophysiology in Interstitial Lung Disease. *Clinics in Chest Medicine*, **2019**, 40, 405-420	5.3	7
67	Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. *BMC Pulmonary Medicine*, **2019**, 19, 192	3.5	14
66	Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2019**, 54,	13.6	5
65	Supplemental oxygen for the management of dyspnea in interstitial lung disease. *Current Opinion in Supportive and Palliative Care*, **2019**, 13, 174-178	2.6	0
64	Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial. *BMC Cancer*, **2019**, 19, 1206	4.8	9
63	Minimal Important Difference for Physical Activity and Validity of the International Physical Activity Questionnaire in Interstitial Lung Disease. *Annals of the American Thoracic Society*, **2019**, 16, 107-115	4.7	6
62	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2019**, 53,	13.6	41
61	YouTube Videos as a Source of Misinformation on Idiopathic Pulmonary Fibrosis. *Annals of the American Thoracic Society*, **2019**, 16, 572-579	4.7	29
60	Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease. *Annals of the American Thoracic Society*, **2019**, 16, 455-462	4.7	21
59	Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease. *Respirology*, **2018**, 23, 921-926	3.6	13
58	Diagnostic criteria for idiopathic pulmonary fibrosis - AuthorsSreply. *Lancet Respiratory Medicine,the* , **2018**, 6, e7	35.1	3

57	Physical activity measurement accuracy in advanced chronic lung disease. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2018**, 2, 9-18	0.6	
56	Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. *European Respiratory Journal*, **2018**, 51,	13.6	20
55	Unclassifiable interstitial lung disease: from phenotyping to possible treatments. *Current Opinion in Pulmonary Medicine*, **2018**, 24, 461-468	3	10
54	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. *Respiration*, **2018**, 96, 314-322	3.7	29
53	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 1036-1044	10.2	109
52	Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. *Respirology*, **2018**, 23, 392-398	3.6	39
51	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respiratory Medicine,the*, **2018**, 6, 138-153	35.1	452
50	Systematic review of content and quality of idiopathic pulmonary fibrosis review articles. *ERJ Open Research*, **2018**, 4,	3.5	1
49	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2018**, 2, 234-243	0.6	6
48	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2018**, 2, 257-258	0.6	
47	Successful lung transplantation in an HIV seropositive patient with desquamative interstitial pneumonia: a case report. *BMC Pulmonary Medicine*, **2018**, 18, 162	3.5	10
46	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, e44-e68	10.2	1426
45	Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. *Annals of the American Thoracic Society*, **2018**, 15, 854-863	4.7	49
44	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1249-1254	10.2	105
43	Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. *Respiratory Medicine*, **2017**, 129, 1-7	4.6	13
42	Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. *Respirology*, **2017**, 22, 1592-1597	3.6	16
41	Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease. *European Respiratory Journal*, **2017**, 49,	13.6	33
40	Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease. *Respirology*, **2017**, 22, 728-734	3.6	24

39	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*, **2017**, 1, 133-141	0.6	11
38	Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2017**, 50,	13.6	19
37	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *European Respiratory Journal*, **2017**, 50,	13.6	50
36	Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence. *European Respiratory Review*, **2017**, 26,	9.8	5
35	Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. *Annals of the American Thoracic Society*, **2017**, 14, 1373-1377	4.7	21
34	Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. *Chest*, **2017**, 151, 619-625	5.3	120
33	Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease. A Systematic Review and Metaanalysis. *Annals of the American Thoracic Society*, **2016**, 13, 1828-1838	4.7	115
32	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 265-75	10.2	653
31	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. *Annals of the American Thoracic Society*, **2016**, 13, 1640-7	4.7	27
30	Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 218-25	10.2	57
29	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. *Canadian Respiratory Journal*, **2016**, 2016, 3562923	2.1	20
28	Frailty and postoperative outcomes in patients undergoing surgery for degenerative spine disease. *Spine Journal*, **2016**, 16, 1315-1323	4	91
27	Unclassifiable interstitial lung disease: A review. *Respirology*, **2016**, 21, 51-6	3.6	36
26	The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2015**, 109, 1058-62	4.6	7
25	Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. *European Respiratory Journal*, **2015**, 46, 512-20	13.6	113
24	Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis. *Chest*, **2015**, 148, 1268-1275	5.3	31
23	Unclassifiable interstitial lung disease: an unresolved diagnostic dilemma. *Respirology Case Reports*, **2015**, 3, 85-8	0.9	5
22	Managing comorbidities in idiopathic pulmonary fibrosis. *International Journal of General Medicine*, **2015**, 8, 309-18	2.3	27

21	Determining respiratory impairment in connective tissue disease-associated interstitial lung disease. *Rheumatic Disease Clinics of North America*, **2015**, 41, 213-23	2.4	6
20	Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. *Respiratory Medicine*, **2014**, 108, 203-10	4.6	114
19	Predicting survival across chronic interstitial lung disease: the ILD-GAP model. *Chest*, **2014**, 145, 723-728	5.3	253
18	Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. *Chest*, **2014**, 146, 422-436	5.3	143
17	Acute exacerbations complicating interstitial lung disease. *Current Opinion in Pulmonary Medicine*, **2014**, 20, 436-41	3	26
16	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 733-48	10.2	2176
15	Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2013**, 107, 249-55	4.6	64
14	Combined pulmonary fibrosis and emphysema. *Current Respiratory Care Reports*, **2013**, 2, 254-259		3
13	Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. *Chest*, **2013**, 144, 586-592	5.3	117
12	Update on the diagnosis and classification of ILD. *Current Opinion in Pulmonary Medicine*, **2013**, 19, 453-93		42
11	Prevalence and prognosis of unclassifiable interstitial lung disease. *European Respiratory Journal*, **2013**, 42, 750-7	13.6	164
10	Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. *Chest*, **2013**, 144, 234-240	5.3	186
9	Dyspnea in idiopathic pulmonary fibrosis: a systematic review. *Journal of Pain and Symptom Management*, **2012**, 43, 771-82	4.8	55
8	Depression is a common and chronic comorbidity in patients with interstitial lung disease. *Respirology*, **2012**, 17, 525-32	3.6	67
7	A multidimensional index and staging system for idiopathic pulmonary fibrosis. *Annals of Internal Medicine*, **2012**, 156, 684-91	8	642
6	Cough predicts prognosis in idiopathic pulmonary fibrosis. *Respirology*, **2011**, 16, 969-75	3.6	94
5	Depression and functional status are strongly associated with dyspnea in interstitial lung disease. *Chest*, **2011**, 139, 609-616	5.3	94
4	Management of dyspnea in interstitial lung disease. *Current Opinion in Supportive and Palliative Care*, **2010**, 4, 69-75	2.6	13

3	Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. *Respiratory Research*, **2010**, 11, 12	7.3	58
2	Canadian Thoracic Society position statement on rehabilitation for COVID-19 and implications for pulmonary rehabilitation. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*,1-5	0.6	3
1	Costs of oxygen therapy for interstitial lung disease and chronic obstructive pulmonary disease: A retrospective study from a universal healthcare system. *Canadian Journal of Respiratory, Critical Care, and Sleep Medicine*,1-8	0.6	